Alpha Tau Medical (DRTS) said Monday the US Food and Drug Administration approved an investigational device exemption supplement for its Alpha DaRT radiation therapy.
The supplement allows for the expansion of the study examining the combination of Alpha DaRT and first-line chemotherapy to include both newly diagnosed metastatic and locally advanced pancreatic cancer patients, increasing the total number of patients to 30 across two cohorts, according to the company.
Shares of Alpha Tau Medical were down 1.6% in recent trading.
Price: 3.64, Change: -0.06, Percent Change: -1.62
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。